Recombinant hepatitis B vaccine for prevention of hepatitis B infection.
Twenty-five resident doctors were given 1 ml (20 micrograms) of recombinant hepatitis B vaccine intramuscularly in the deltoid region at 0, 1 and 6 months. Seroconversion rates at 1, 2, 3, 7 and 8 months were 8%, 48%, 64%, 96% and 100% respectively. Acceptability of the vaccine was 100%. The recombinant hepatitis B vaccine is safe and efficacious, with seroconversion rates comparable to the plasma derived vaccine, and has negligible side effects.
Gill
H H
HH
Department of Gastroenterology, BYL Nair Ch Hospital, Bombay.
Desai
H G
HG
Trikannad
V S
VS
D000328:Adult; D005260:Female; D006509:Hepatitis B / Q000517:prevention & control*; D017325:Hepatitis B Vaccines; D006801:Humans; D008297:Male; D009784:Occupational Diseases / Q000517:prevention & control*; D010820:Physicians; D011994:Recombinant Proteins; D013997:Time Factors; D014611:Vaccination; D014761:Viral Hepatitis Vaccines
D017325:Hepatitis B Vaccines; D011994:Recombinant Proteins; D014761:Viral Hepatitis Vaccines